Treatment and cure strategies for WHIM syndrome immunodeficiency

Philip Murphy


Dr. Murphy is Chief of the Laboratory of Molecular Immunology at the National Institute of Allergy and Infectious Diseases of the National Institutes of Health. His research focuses on leukocyte chemotactic receptors, from their basic molecular and biologic properties to their roles in human disease, including HIV/AIDS, atherosclerosis, West Nile virus infection and WHIM syndrome immunodeficiency.  He is currently developing mechanism-based personalized treatment and cure strategies for patients with WHIM syndrome, including chronic plerixafor therapy, gene therapy and allotransplantation.   


Gain-of-function mutations in chemokine receptor CXCR4 cause the autosomal dominant immunodeficiency disorder WHIM syndrome. We have conducted a Phase 1 clinical trial of plerixafor, a specific CXCR4 antagonist, in patients... [ view full abstract ]


  1. Philip Murphy (NIH)

Topic Areas

Drug target discovery and integration with individualized therapy, integration of diagnosi , Personalized therapies (cancer, immunology, infectious diseases, clinical case studies, et


PL3b » Plenary Speeches (10:45 - Wednesday, 27th June, Amphitheater)

Presentation Files

The presenter has not uploaded any presentation files.